Roivant Sciences Ltd. (ROIV)Healthcare | Biotechnology | London, United Kingdom | NasdaqGS
34.51 USD
-1.46
(-4.059%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 34.53 +0.02 (0.058%) ⇧ (July 13, 2026, 6:38 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:53 a.m. EDT
The investment case for Roivant is fundamentally broken despite the 'strong buy' analyst consensus. The company is hemorrhaging cash with negative free cash flow of nearly $1.1 billion and operating margins of -146%, while revenue has contracted by two-thirds year-over-year. Trading at a forward P/E of -23 and a price-to-book of 5.7x, the stock is priced as if the business will recover, yet the balance sheet shows no path to profitability without massive dilution or asset sales. The recent price action is a deceptive technical breakout; the underlying reality is a deteriorating biotech franchise with no sustainable revenue growth. The options market confirms this skepticism, with traders stacking heavy put positions at strikes far below the current price, betting on a collapse rather than a recovery. This is a classic value trap where the market is pricing in a disaster that the fundamentals clearly support. |
| Model | MAE |
|---|---|
| MSTL_126 ✓ | 0.052038 |
| AutoTheta | 0.054882 |
| MSTL | 0.060285 |
| AutoARIMA | 0.061599 |
| AutoETS | 0.061599 |
Forecast horizon: 60 days | Selected: MSTL_126
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 2.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.007 |
| Excess Kurtosis | -0.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.03 |
| Revenue per Share | 0.012 |
| Market Cap | 24,822,020,096 |
| Forward P/E | -22.13 |
| Beta | 1.11 |
| Website | https://roivant.com |
As of July 11, 2026, 5:53 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 10, 17, 20, 21, 27) compared to negligible call volume. While there is some activity in near-term calls around the $36-$38 strikes, the overwhelming capital allocation is in deep OTM puts, suggesting a fear of a significant drop rather than a belief in a rally. Implied volatility is elevated on these protective strikes, indicating the market prices in a high probability of a crash.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.0928633 |
| Address1 | 50 Broadway |
| Address2 | 7th Floor |
| All Time High | 37.0 |
| All Time Low | 2.52 |
| Ask | 37.54 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 6,234,820 |
| Average Daily Volume3 Month | 6,055,836 |
| Average Volume | 6,055,836 |
| Average Volume10Days | 6,234,820 |
| Beta | 1.108 |
| Bid | 34.49 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 6.285 |
| City | London |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.51 |
| Current Ratio | 18.373 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 35.62 |
| Day Low | 34.375 |
| Debt To Equity | 2.03 |
| Display Name | Roivant Sciences |
| Earnings Call Timestamp End | 1,748,520,000 |
| Earnings Call Timestamp Start | 1,748,520,000 |
| Earnings Timestamp | 1,779,280,200 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -1,276,555,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -16.766 |
| Enterprise To Revenue | 2,591.122 |
| Enterprise Value | 21,402,667,008 |
| Eps Current Year | -1.49573 |
| Eps Forward | -1.55935 |
| Eps Trailing Twelve Months | -0.54 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.8211 |
| Fifty Day Average Change | 3.688898 |
| Fifty Day Average Change Percent | 0.11968742 |
| Fifty Two Week Change Percent | 209.28633 |
| Fifty Two Week High | 37.0 |
| Fifty Two Week High Change | -2.4900017 |
| Fifty Two Week High Change Percent | -0.06729734 |
| Fifty Two Week Low | 10.9 |
| Fifty Two Week Low Change | 23.609999 |
| Fifty Two Week Low Change Percent | 2.166055 |
| Fifty Two Week Range | 10.9 - 37.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,607,437,800,000 |
| Float Shares | 563,987,102 |
| Forward Eps | -1.55935 |
| Forward P E | -22.131016 |
| Free Cashflow | -1,090,485,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 721 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -673,937,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23385 |
| Held Percent Institutions | 0.76067 |
| Implied Shares Outstanding | 719,270,385 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,774,915,200 |
| Long Business Summary | Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom. |
| Long Name | Roivant Sciences Ltd. |
| Market | us_market |
| Market Cap | 24,822,020,096 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_282015801 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -299,771,008 |
| Next Fiscal Year End | 1,806,451,200 |
| Non Diluted Market Cap | 25,872,155,748 |
| Number Of Analyst Opinions | 12 |
| Open | 35.4 |
| Operating Cashflow | -750,348,992 |
| Operating Margins | -146.75082 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 44 20 7400 3347 |
| Post Market Change | 0.020000458 |
| Post Market Change Percent | 0.057955544 |
| Post Market Price | 34.53 |
| Post Market Time | 1,783,982,311 |
| Previous Close | 35.97 |
| Price Eps Current Year | -23.072344 |
| Price Hint | 2 |
| Price To Book | 5.490851 |
| Price To Sales Trailing12 Months | 3,005.0872 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.999 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.30769 |
| Region | US |
| Regular Market Change | -1.46 |
| Regular Market Change Percent | -4.05895 |
| Regular Market Day High | 35.62 |
| Regular Market Day Low | 34.375 |
| Regular Market Day Range | 34.375 - 35.62 |
| Regular Market Open | 35.4 |
| Regular Market Previous Close | 35.97 |
| Regular Market Price | 34.51 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 4,743,478 |
| Return On Assets | -0.14354 |
| Return On Equity | -0.07594 |
| Revenue Growth | -0.667 |
| Revenue Per Share | 0.012 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 719,270,385 |
| Shares Percent Shares Out | 0.0462 |
| Shares Short | 33,212,917 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 36,233,835 |
| Short Name | Roivant Sciences Ltd. |
| Short Percent Of Float | 0.060900003 |
| Short Ratio | 5.42 |
| Source Interval | 15 |
| Symbol | ROIV |
| Target High Price | 49.0 |
| Target Low Price | 31.5 |
| Target Mean Price | 39.375 |
| Target Median Price | 40.0 |
| Total Cash | 4,291,833,088 |
| Total Cash Per Share | 5.967 |
| Total Debt | 107,438,000 |
| Total Revenue | 8,260,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.54 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.012026 |
| Two Hundred Day Average Change | 9.4979725 |
| Two Hundred Day Average Change Percent | 0.37973624 |
| Type Disp | Equity |
| Volume | 4,743,478 |
| Website | https://roivant.com |
| Zip | SW1H 0DB |